UK Markets closed
  • FTSE 100

    7,258.32
    +49.51 (+0.69%)
     
  • FTSE 250

    19,318.95
    +195.24 (+1.02%)
     
  • AIM

    903.49
    +7.22 (+0.81%)
     
  • GBP/EUR

    1.1599
    -0.0019 (-0.16%)
     
  • GBP/USD

    1.2300
    +0.0030 (+0.2423%)
     
  • BTC-GBP

    16,855.16
    -566.96 (-3.25%)
     
  • CMC Crypto 200

    451.50
    -10.29 (-2.23%)
     
  • S&P 500

    3,912.70
    +0.96 (+0.02%)
     
  • DOW

    31,517.43
    +16.75 (+0.05%)
     
  • CRUDE OIL

    109.06
    +1.44 (+1.34%)
     
  • GOLD FUTURES

    1,826.30
    -4.00 (-0.22%)
     
  • NIKKEI 225

    26,871.27
    +379.30 (+1.43%)
     
  • HANG SENG

    22,229.52
    +510.46 (+2.35%)
     
  • DAX

    13,186.07
    +67.94 (+0.52%)
     
  • CAC 40

    6,047.31
    -26.04 (-0.43%)
     

Genitourinary Partnering Global Database 2010 to 2022 - Financial Deal Terms for Headline, Upfront and Royalty by Stage of Development

·6-min read
Company Logo
Company Logo

Dublin, June 21, 2022 (GLOBE NEWSWIRE) -- The "Global Genitourinary Partnering 2010-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

This report provides the full collection of Genitourinary disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Genitourinary partnering deals

  • Financial deal terms for headline, upfront and royalty by stage of development

  • Genitourinary partnering agreement structure

  • Genitourinary partnering contract documents

  • Top Genitourinary deals by value

  • Most active Genitourinary dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genitourinary disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genitourinary deals.

The report presents financial deal terms values for Genitourinary deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

Report scope

Global Genitourinary Partnering 2010 to 2022 is intended to provide the reader with an in-depth understanding and access to Genitourinary trends and structure of deals entered into by leading companies worldwide.

Global Genitourinary Partnering 2010 to 2022 includes:

  • Trends in Genitourinary dealmaking in the biopharma industry since 2010

  • Access to headline, upfront, milestone and royalty data

  • Access to hundreds of Genitourinary deal contract documents

  • Comprehensive access to over 680 Genitourinary deal records

  • The leading Genitourinary deals by value since 2010

  • Most active Genitourinary dealmakers since 2010

The report includes deals for the following indications: Discharge, Frequency, Incontinence, Itching, Nocturia, Urgency, Acute kidney injury, Amyloidosis, Chronic kidney disease (CKD), Cystitis, Diabetic nephropathy, Dialysis, Hemolytic-uremic syndrome (HUS), Kidney stones, Nephrotic syndrom, Overactive bladder, Peyronie's disease, Polycystic kidney disease, Prostate diseases, Prostatitis, Prostate enlargement, Renal failure, Renal infections, Nephritis, Glomerulonephritis, Pyelonephritis, Vesicoureteral reflux, Urinary tract infection (UTI), plus other genitourinary indications.

In Global Genitourinary Partnering 2010 to 2022, available deals and contracts are listed by:

  • Headline value

  • Upfront payment value

  • Royalty rate value

  • Stage of development at signing

  • Deal component type

  • Technology type

  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Genitourinary Partnering 2010 to 2022 report provides comprehensive access to available deals and contract documents for over 570 Genitourinary deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise Genitourinary rights granted or optioned?

  • What is actually granted by the agreement to the partner company?

  • What exclusivity is granted?

  • What is the payment structure for the deal?

  • How are sales and payments audited?

  • What is the deal term?

  • How are the key terms of the agreement defined?

  • How are IPRs handled and owned?

  • Who is responsible for commercialization?

  • Who is responsible for development, supply, and manufacture?

  • How is confidentiality and publication managed?

  • How are disputes to be resolved?

  • Under what conditions can the deal be terminated?

  • What happens when there is a change of ownership?

  • What sublicensing and subcontracting provisions have been agreed?

  • Which boilerplate clauses does the company insist upon?

  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

  • Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Genitourinary dealmaking
2.1. Introduction
2.2. Genitourinary partnering over the years
2.3. Genitourinary partnering by deal type
2.4. Genitourinary partnering by industry sector
2.5. Genitourinary partnering by stage of development
2.6. Genitourinary partnering by technology type
2.7. Genitourinary partnering by therapeutic indication

Chapter 3 -Financial deal terms for Genitourinary partnering
3.1. Introduction
3.2. Disclosed financials terms for Genitourinary partnering
3.3. Genitourinary partnering headline values
3.4. Genitourinary deal upfront payments
3.5. Genitourinary deal milestone payments
3.6. Genitourinary royalty rates

Chapter 4 - Leading Genitourinary deals and dealmakers
4.1. Introduction
4.2. Most active in Genitourinary partnering
4.3. List of most active dealmakers in Genitourinary
4.4. Top Genitourinary deals by value

Chapter 5 - Genitourinary contract document directory
5.1. Introduction
5.2. Genitourinary partnering deals where contract document available

Chapter 6 - Genitourinary dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Genitourinary therapeutic target

Companies Mentioned

  • 3SBio

  • 4D Science

  • 180 Medical

  • A1M Pharma

  • AbbeyMoor Medical

  • Abbott Laboratories

  • Abbvie

  • Acer Therapeutics

  • Acerus

  • Aceso Life Science

  • Aceto Corporation

  • Acino Pharma

  • ACIST Medical Systems

  • Acon Labs

  • Actient Pharmaceuticals

  • Action Pharma

  • ActivStyle

  • Acurx Pharmaceuticals

  • AdaptHealth

  • Aduro BioTech

  • Advanced Uro-Solutions

  • Advanz Pharma

  • Advicenne

  • AEterna Zentaris

  • Aethlon Medical

  • Aetna

  • Affymax

  • AirStrip Technologies

  • Akcea Therapeutics

  • Akebia Therapeutics

  • AKESOgen

  • Alavita Pharmaceuticals

  • AlCana Technologies

  • Alcavis HDC

  • Alere Health

  • Algernon Pharmaceuticals

  • Alio Medical

  • AliveCor

  • Alivio Therapeutics

  • Allecra Therapeutics

  • Allegis Pharmaceuticals

  • Allena Pharmaceuticals

  • Allergan

  • Allium Medical Solutions

  • Alnylam Pharmaceuticals

  • Altasciences

  • Altavant Sciences

  • Althea Technologies

  • AltheRx

  • AM-Pharma

  • Amag Pharmaceuticals

  • Ambu

  • American Access Care

  • American Diabetes Association

  • American Lung Association

  • American Medical Systems

  • American Renal Associates

  • American Urological Association

  • Amerigen Pharmaceuticals

  • Amerinet

  • AmerisourceBergen

  • Amgen

  • AmorChem

  • Ampio Pharmaceuticals

  • Amplity Health

  • Anakuria Therapeutics

  • ANDROMEDA Medizinische Systems

  • Angelini Pharma

  • Angion Biomedica

  • Angiotech Pharmaceuticals

  • ANI Pharmaceuticals

  • Antares Pharma

  • Anteris Bio

  • Anthem

  • Anthem Bluecross

  • Anthera Pharmaceuticals

  • AorTech

  • Apax Partners

  • Apellis Pharmaceuticals

  • Apocell

  • Apollo Hospitals Group

  • Applied Medical

  • Aquestive Therapeutics

  • Aquinox Pharmaceuticals

  • Arch Biopartners

  • Archimedes Pharma

  • Ardelyx

  • Arena Pharmaceuticals

  • Argon Medical Devices

  • Argutus Medical

  • Arizona State University

  • Arkray USA

  • Arrevus

  • Arriani Pharmaceuticals

  • Asahi Kasei

  • Ascend Clinical

  • Ascend Therapeutics

  • ASC Therapeutics

  • ASD Speciality Healthcare

  • Asia Renal Care

  • ASKA Pharmaceuticals

  • Aspect Biosystems

  • Assembly Biosciences

  • Astellas Pharma

  • Astellas Pharma US

  • AstraZeneca

  • Astute Medical

  • Atara Biotherapeutics

  • Atlantic Dialysis Management Services

  • Aurinia Pharmaceuticals

  • Auven Therapeutics

  • Auxilium Pharmaceuticals

  • Avanti Specialty Pharmacy Management

  • Avenu Medical

  • AWAK Technologies

  • Axonics Modulation Technologies

  • Ayogo Health

  • Aytu BioPharma

  • Aziyo Biologics

  • Balboa Nephrology Medical Group

  • Bausch & Lomb

  • Baxter International

  • Baylor Health Care System

  • B Braun

  • Beacon Discovery

  • Beckman Coulter

  • Becton Dickinson

  • Beijing King Health

  • Beijing Leadman Biochemistry

  • Bellco Health Care

  • Bellus Health

  • BenevolentAI

  • Beth Israel Deaconess Medical Center

  • Biim Ultrasound

  • Bio-Techne

  • BIOASTER

  • BioCad Holding

  • Biocon

  • BioDerm

  • BioLink Life Sciences

  • Biomedical Advanced Research and Development Authority

  • Biomerica

  • bioMerieux

  • BioPorto

  • BioSerenity

  • Biostar Pharmaceuticals

  • BioVectra

  • BK Medical

  • Blackstone

  • Bladder Health Network

  • Blue Cross Blue Shield Association

  • Boehringer Ingelheim

  • Boston Scientific

  • Bridge Medicines

For more information about this report visit https://www.researchandmarkets.com/r/kehchy

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting